sCEACAM-1 levels in maternal blood in case of threatened preterm birth

被引：0
作者：
Zaimi, Bora [1 ]
Bazzano, Maria Victoria [1 ,2 ]
Rauh, Maximilian [1 ]
Solano, Maria Emilia [1 ,2 ]
Kappelmeyer, Maurice [1 ,2 ]
Koeninger, Angela
机构：
[1] Univ Regensburg, Univ Dept Obstet & Gynaecol, Clin St Hedwig Order St John, Steinmetzstr 1-3, D-93049 Regensburg, Germany
[2] Univ Regensburg, Lab Translat Perinatol, Biopk 1-3, D-93053 Regensburg, Germany
来源：
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY | 2025年 / 307卷
关键词：
CEACAM1; Preterm birth; Preterm premature rupture of membranes; Immune tolerance; Pregnancy complications; CELL-ADHESION MOLECULE-1; CEACAM1; PROTEIN; IMMUNE-SYSTEM; PREGNANCY; IMPLANTATION; EXPRESSION; APOPTOSIS; CEA;
D O I：
10.1016/j.ejogrb.2025.02.025
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Introduction: This study aims to investigate the role of CEACAM1 in preterm birth. Preterm birth is a phenomenon with numerous triggers, with the immune system hypothesized to play a significant role in the process, aligning with the concept of 'birth as an immunological rejection phenomenon'. There are several approaches to predict preterm birth, and the determination of sCEACAM1 levels, a member of the carcinoembryonic antigen family, may serve as a potential candidate biomarker. Methods: A single-center prospective case series study included 67 pregnant women aged 18 years or older who presented before 37 weeks of gestation with signs of preterm birth in the years 2021-2023. At the time of admission, CEACAM1 was determined in maternal blood. Results: The median sCEACAM1 levels were significantly higher in women who delivered preterm compared to those who delivered at term respectively, 5014 pg/ml (IQR: 3592-8826) vs. 3353 pg/ml (IQR: 2354-5049) (p = 0.016). The median sCEACAM1 level in the group with PPROM (premature preterm rupture of membranes) at 34 weeks' gestation was 7001 pg/ml (IQR: 5683-13509), while the median sCEACAM1 level in the group without PPROM at 34 weeks' gestation was 3884 pg/ml (IQR; 2461-4985) (p < 0.001). Conclusions: Pregnant women with preterm birth and/or PPROM before 34 weeks' gestation have higher CEACAM1 levels compared to women with threatened preterm labor who finally had labot at term. The results suggest early activated immune system as a potential pathomechanism of preterm delivery.
引用
收藏
页码：230 / 235
页数：6
相关论文
共 44 条
  • [1] O'Reilly P., Dakin A., Keating N., Luethe L., Corcoran S., Does the use of gestation-specific centiles for cervical length change the management of pregnancies at risk of recurrent spontaneous preterm birth?, Eur J Obstet Gynecol Reprod Biol, pp. 264349-264352, (2021)
  • [2] World Health Organization
  • [3] Liu T., Xu Y., Gong Y., Zheng J., Chen Z., The global burden of disease attributable to preterm birth and low birth weight in 204 countries and territories from 1990 to 2019: an analysis of the Global Burden of Disease Study, J Glob Health, 2024, (1990)
  • [4] Esposito G., Mauri P.A., Cipriani S., Franchi M., Corrao G., Parazzini F., The role of maternal age on the risk of preterm birth among singletons and multiples: a retrospective cohort study in Lombardy, Norther Italy, BMC Pregnancy Childbirth, 22, 1, (2022)
  • [5] Goldenberg R.L., Culhane J.F., Iams J.D., Romero R., Preterm birth 1: epidemiology and causes of preterm birth, Obstet Anesth Dig, 29, 1, pp. 6-7, (2009)
  • [6] Oskovi Kaplan Z.A., Ozgu-Erdinc A.S., Prediction of preterm birth: maternal characteristics, ultrasound markers, and biomarkers: an updated overview, J Pregnancy, (2018)
  • [7] Pirjani R., Moini A., Almasi-Hashiani A., Farid Mojtahedi M., Vesali S., Hosseini L., Et al., Placental alpha microglobulin-1 (PartoSure) test for the prediction of preterm birth: a systematic review and meta-analysis, J Matern Fetal Neonatal Med, 34, 20, pp. 3445-3457, (2021)
  • [8] Tsugawa N., Yamada D., Watabe T., Onizawa M., Wang S., Nemoto Y., Oshima S., Tsubata T., Adachi T., Kawano Y., Watanabe M., Blumberg R.S., Okamoto R., Nagaishi T., CEACAM1 specifically suppresses B cell receptor signaling-mediated activation, Biochem Biophys Res Commun, pp. 53599-54105, (2021)
  • [9] Thomas J., Klebanov A., John S., Miller L.S., Vegesna A., Amdur R.L., Bhowmick K., Mishra L., CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens, Genes Cancer, pp. 1412-1429, (2023)
  • [10] Markel G., Wolf D., Hanna J., Gazit R., Goldman-Wohl D., Lavy Y., Et al., Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions, J Clin Invest, 110, 7, pp. 943-953, (2002)
12345